Early Dementia Distinguishing AD From MCI

Slides:



Advertisements
Similar presentations
Living well with dementia: more timely diagnosis and early intervention Louise Robinson Professor of Primary Care and Ageing RCGP National Clinical Champion.
Advertisements

Neurocognitive Disorders
FM&PHC HKWC Hospital Authority Family Doctor Your Health Partner Dr. Wang Hua Li, Jenny LMCHK, FKCFP, FRACGP, FHKAM (FM) Associate Consultant In-charge.
The National Task Group Early Detection Screen for Dementia
Risk of Developing Alzheimer’s Disease in Persons with MCI
Non-pharmacologic Management There is good evidence to recommend an individualized exercise program for patients with mild to moderate dementia – A simple.
Defining Mild Cognitive Impairment Steven T.DeKosky, M.D. Director, Alzheimer’s Disease Research Center University of Pittsburgh Pittsburgh, PA.
COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.
The Worldwide Epidemic of Senile Dementias- Challenges of Pre-Clinical Treatment Evolving Diagnostic Approaches Dimitrios Kapogiannis AAAS 2015 Annual.
1 From Cause to Movement Shaping a World Without Alzheimer’s Through Advocacy, Volunteerism, Referral and Science Ian Kremer, Esq. Advocacy & Outreach.
Alzheimer’s Disease  Goals  To understand what dementia is  To explore causes, risk factors, symptoms, and treatments of Alzheimer’s Disease  To better.
How to diagnose dementia? Dr. Sridhar Vaitheswaran 25 th October 2012.
1 Mosby items and derived items © 2011, 2007 by Mosby, Inc., an affiliate of Elsevier, Inc. Chapter 60 Nursing Management: Alzheimer's Disease, Dementia,
PZP: A novel biomarker for early Alzheimer’s disease ? Diana A.T. Nijholt Department of Neurology Laboratory for Clinical and Cancer Proteomics
Dementia: Alzheimer’s Disease Cyril Evbuomwan Patient Group Meeting 1 st December 2015.
Recent advances in Trace Element Research in Health and Disease Dubrovnik, Oct 2015 Mirjana Babić Leko, mag.biol.mol Department of Neuroscience Croatian.
We Treat Alzheimers 20 years early? Can. Clinical neurologist-Reisa Sperling 1. Is a clinical neurologist, a neuroimaging researcher. 2.Is a leading force.
The clinical research of early diagnosis and ultimately the treatment of Alzheimer’s disease 許一仁 董冠廷 詹鎮遠 陳柏廷.
Apolipoprotein E and Gray Matter Loss in Mild Cognitive Impairment and Alzheimer’s Disease Spampinato MV, Goldsberry G, Mintzer J, Rumboldt Z Medical University.
Cognitive Development Dementia. Stages: Preclinical First sign: memory loss for the familiar First sign: memory loss for the familiar Biological changes.
Wrexham and Flintshire memory service Presenters: DR. SHARMI BHATTACHARYYA, Consultant IAN DAVIES ABBOTT, Clinical Nurse Specialist ROWENNA SPENCER, Manager.
Date of download: 7/8/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Intranasal Insulin Therapy for Alzheimer Disease and.
Dementia F.Etessam. MD. Dementia A progressive impairment of cognitive functions occurring in clear consciousness.
Alzheimer Disease: An Overview. What is Dementia? Dementia is a set of symptoms, which includes loss of memory, understanding, and judgment.
DIAGNOSTIC ACCURACY AND CONFIDENCE IN THE CLINICAL DETECTION OF COGNITIVE IMPAIRMENT IN EARLY-STAGE PARKINSON’S DISEASE  Kathryn A. Wyman-Chick, Phillip.
Value of cerebrospinal fluid visinin-like protein-1 (VILIP-1) for prediction of mild cognitive impairment progression to Alzheimer's disease  Mirjana Babić.
Volume 3, Issue 4, Pages (November 2017)
Arg-ADNI Patients’ Flowchart Patients Invited to ADNI Nº= 73
Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer's disease in a memory clinic sample  Marie Eckerström,
Neuroticism, depression, and anxiety traits exacerbate the state of cognitive impairment and hippocampal vulnerability to Alzheimer's disease  Valérie.
The differential diagnosis of amnestic mild cognitive impairment and Alzheimer's disease dementia by hippocampal volume measurement with MR in a chinese.
Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire  Roos J.
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
An amylin analog used as a challenge test for Alzheimer's disease
Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline  Sander C.J.
Volume 2, Issue 1, Pages (January 2016)
Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin  Eva Carro, Fernando Bartolomé, Félix Bermejo-Pareja,
Imaging AD Progression Amyloid Imaging Agents.
A Common Clinical Challenge: Neonatal Jaundice Is it Physiologic or Pathologic?
Cognitive Disorders and Aging
Treatment Strategies in Mild to Moderate COPD
Essential Updates in Atopic Dermatitis:
Diagnosing Rheumatoid Arthritis Early
Modifying Disease Course in Alzheimer's Disease
Progression After Cancer Immunotherapy in Advanced NSCLC
Figure 1 Hypothetical staging model of sporadic Alzheimer disease (AD)
Seasonal Allergic Rhinitis
Early Cognitive Decline and the Aging Brain - Overview
Chronic Idiopathic Urticaria
Mild Cognitive Impairment and Mild Dementia: A Clinical Perspective
Addressing Disease Burden in Asthma
Asthma and Atopic Comorbidities
Tackling Atopic Dermatitis
Chapter 93 Dementias and Related Disorders
The EMPIR NeuroMET project
Current and Emerging Strategies for Management of Moderate-to-Severe Atopic Dermatitis.
Introduction to AD. Practical Approaches to the Identification of Alzheimer Disease in Primary Care.
Management of Systemic Lupus Erythematosus
Epidemiology of Dementias
Early cost-utility analysis of general and cerebrospinal fluid-specific Alzheimer's disease biomarkers for hypothetical disease-modifying treatment decision.
Interreg-IPA Cross-border Cooperation Programme Romania-Serbia
Confusion and Dementia
The Building Blocks of Homocystinuria and Homocysteinemia Management
Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients  Eric R. Siemers, Karen L. Sundell, Christopher Carlson, Michael Case,
Alzheimer's & Dementia: The Journal of the Alzheimer's Association
GREY MATTER CONNECTIVITY IS ASSOCIATED WITH CLINICAL PROGRESSION IN NON-DEMENTED, AMYLOID POSITIVE PATIENTS  Betty M. Tijms, Mara ten Kate, Sander C.J.
Alzheimer's Prevention Research and
Ongoing Research With Vascular Risk Factors and the RAS in Individuals at Risk for AD Whitney Wharton, PhD Assistant Professor,
Fig. 1. ROC curve for K-IADL to diagnose dementia or MCI
Box plot showing the distribution of the TYM-MCI score for patients with SMC and aMCI/AD. aMCI/AD, amnestic mild cognitive impairment or Alzheimer’s disease;
Presentation transcript:

Case-Based Approach: Early Identification and Management of Alzheimer Disease

Early Dementia Distinguishing AD From MCI

Clinical Case Rachel S.

Ages of People With AD in the United States

Cognitive Changes and Occupation

Differential Diagnosis of AD

Assessing Language Function

Declining Ability to Function

Mood and Emotional Changes

Cognitive Impairment

Laboratory Investigations in AD

Cognitive Testing in AD

Biomarker Testing

Hippocampal Volume Assessment

Treatment of Patients With Mild AD

Nutritional Interventions in AD and MCI

When to Refer to a Specialist?

Concluding Remarks

Abbreviations

Abbreviations